Volume 25, Number 3—March 2019
University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018
|State of university
||Primary MenB vaccine
||Cases after vaccine implementation
|New Jersey||MenB-4C†||Mass vaccination campaign||Dose 1, 95%; dose 2, 89%||1|
|California||MenB-4C†||Mass vaccination campaign||Dose 1, 51%; dose 2, 40%||0|
|Rhode Island||MenB-FHbp||Mass vaccination campaign||Dose 1, 94%; dose 2, 80%; dose 3, 77%‡||0|
|Oregon||MenB-FHbp§||Mass vaccination campaigns; student health; local pharmacies||Dose 1, 52%; dose 2, 40%; dose 3, 10%||3¶|
|California||MenB-4C||Mass vaccination campaign||Dose 1, 90%; dose 2, 90%#||0|
|New Jersey||MenB-FHbp||Local providers/pharmacies; student health; some vaccination campaigns||NA||0|
|Wisconsin||MenB-4C||Mass vaccination campaign||Dose 1, 67%; dose 2, >31%**||1¶|
|Oregon||MenB-4C||Mass vaccination campaign with targeted student groups; vaccine requirement||Dose 1, 98%; dose 2, 93%||2|
|Massachusetts††||MenB-4C||Mass vaccination campaign; student health; providers/pharmacies||Dose 1, 34%**,‡‡; dose 2, 16%||1|
|Pennsylvania||MenB-4C||Vaccinated athletic team; campus-wide recommendation for vaccination at student health||Dose 1, 14%; dose 2, 2%**||0|
*MenB, serogroup B meningococcal; MenB-4C, Bexsero (GlaxoSmithKline, https://www.gsk.com); MenB-FHbp, Trumenba (Pfizer, https://www.pfizer.com); NA, vaccination coverage estimates not available.
†Vaccine available through a CDC-sponsored investigational new drug protocol.
‡Coverage data refer to 2015 campaign. Incoming freshmen and returning study abroad students were also vaccinated in 2015–2016.
§MenB-4C was also used in response to this outbreak; 21% of students completed either vaccine series. Presented coverage data for this university are as of July 2018.
¶One case in each of these outbreaks occurred 6 days after MenB vaccination efforts commenced, thus prior to any expected immunity.
#This coverage estimate represents the number of persons vaccinated in the second campaign, which likely included some first doses.
**Reported coverage reflects only vaccine doses given on campus; additional students received vaccine doses from providers or pharmacies at home or in other states.
††Cases occurred at 2 universities in a college consortium in the same geographic area. The first 2 cases occurred at university 1 and the third case occurred at university 2. Both universities began vaccination efforts following the second case.
‡‡Combined first-dose coverage data for both universities are presented in the table. First-dose coverage was 33% at university 1 (23,388 undergraduates) and 41% at university 2 (2,500 undergraduates) (Figure 2). Vaccination was ongoing at the time of publication; therefore, data should be considered preliminary.
1Members of the group are listed at the end of this article.